Gyre Therapeutics Inc
NASDAQ:GYRE

Watchlist Manager
Gyre Therapeutics Inc Logo
Gyre Therapeutics Inc
NASDAQ:GYRE
Watchlist
Price: 7.52 USD 3.16% Market Closed
Market Cap: 649.2m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+2%
Revenue
Forecast
+21%
Operating Income
Forecast
N/A
Net Income
Forecast
+30%

Wall Street
Price Targets

GYRE Price Targets Summary
Gyre Therapeutics Inc

Wall Street analysts forecast GYRE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GYRE is 20.4 USD with a low forecast of 20.2 USD and a high forecast of 21 USD.

GYRE Lowest Forecast
Wall Street Target
20.2 USD
169% Upside
GYRE Average Forecast
Wall Street Target
20.4 USD
171% Upside
GYRE Highest Forecast
Wall Street Target
21 USD
179% Upside
Lowest
Price Target
20.2 USD
169% Upside
Average
Price Target
20.4 USD
171% Upside
Highest
Price Target
21 USD
179% Upside
Gyre Therapeutics Inc Competitors:
Price Targets
CYTK
Cytokinetics Inc
108% Upside
GILD
Gilead Sciences Inc
9% Upside
A
ACLX
Arcellx Inc
99% Upside
ASND
Ascendis Pharma A/S
40% Upside
CYTK
Cytokinetics Inc
108% Upside
GILD
Gilead Sciences Inc
9% Upside
A
ACLX
Arcellx Inc
99% Upside
ASND
Ascendis Pharma A/S
40% Upside
302440
SK Bioscience Co Ltd
30% Upside
B
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
24% Upside
6160
Beigene Ltd
27% Upside
LTRN
Lantern Pharma Inc.
599% Upside

Revenue
Forecast

Revenue Estimate
Gyre Therapeutics Inc

For the last 8 years the compound annual growth rate for Gyre Therapeutics Inc's revenue is 101%. The projected CAGR for the next 3 years is 51%.

101%
Past Growth
51%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Gyre Therapeutics Inc

The compound annual growth rate of Gyre Therapeutics Inc's operating income for the next 3 years is 130%.

N/A
Past Growth
130%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Gyre Therapeutics Inc

The compound annual growth rate of Gyre Therapeutics Inc's net income for the next 3 years is 132%.

N/A
Past Growth
132%
Estimated Growth
Estimates Accuracy
-99%
Average Miss
What are analyst estimates?

See Also

Summary
GYRE intrinsic value, competitors valuation, and company profile.
DCF Valuation
GYRE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GYRE stock valuation using valuation multiples.
Wall Street Estimates
GYRE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GYRE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GYRE's stock price target?
Price Target
20.4 USD

According to Wall Street analysts, the average 1-year price target for GYRE is 20.4 USD with a low forecast of 20.2 USD and a high forecast of 21 USD.

What is Gyre Therapeutics Inc's Revenue forecast?
Projected CAGR
51%

For the last 8 years the compound annual growth rate for Gyre Therapeutics Inc's revenue is 101%. The projected CAGR for the next 3 years is 51%.

What is Gyre Therapeutics Inc's Operating Income forecast?
Projected CAGR
130%

The compound annual growth rate of Gyre Therapeutics Inc's operating income for the next 3 years is 130%.

What is Gyre Therapeutics Inc's Net Income forecast?
Projected CAGR
132%

The compound annual growth rate of Gyre Therapeutics Inc's net income for the next 3 years is 132%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 246,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.